# MTS109 in Patients With Refractory Autoimmune Diseases

> **NCT07526350** · EARLY_PHASE1 · RECRUITING · sponsor: **Shanghai Changzheng Hospital** · enrollment: 15 (estimated)

## Conditions studied

- Systemic Lupus Erythematosus
- Idiopathic Inflammatory Myopathies
- Systemic Sclerosis (SSc)
- ANCA-Associated Vasculitis (AAV)
- Sjogren's Syndrome (SS)

## Interventions

- **DRUG:** MTS109

## Key facts

- **NCT ID:** NCT07526350
- **Lead sponsor:** Shanghai Changzheng Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-24
- **Primary completion:** 2028-04-01
- **Final completion:** 2029-04-01
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-04-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07526350

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07526350, "MTS109 in Patients With Refractory Autoimmune Diseases". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT07526350. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*